Full Press Release Details
Zymeworks Announces New Director Nominee.
ZYME
Zymeworks Announces New Director Nominee
Key Takeaway: Zymeworks Announces New Director Nominee
Price reaction · baseline $6.5 (2023-10-13 close) · 1 other ZYME headline(s) in the window, move may be shared
day 0 close
+8.5%
day 1 · peak
+11.5%
day 3
+10.9%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers